Validation Study With a Non-CE Marked Medical Device (MD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Cough
- Sponsor
- Siva Health AG
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Performance of the SIVA-MVP cough detection device
- Status
- Completed
- Last Updated
- 11 months ago
Overview
Brief Summary
This interventional study aims to validate the cough detection device by automatically and continuously measuring the cough frequency with SIVA-MVP among chronic cough patients and in a real-world environment.
Detailed Description
After chronic cough diagnosis, the Principal Investigator (or his designee) will identify potentially eligible patients to participate in this study based on the predefined inclusion criteria. The study will recruit patients with a cough that has lasted for at least 12 months and persistent for the previous 8 weeks with a diagnosis or suspicion of refractory chronic cough, or patients with a diagnosed asthma. A total of 50 patients will be enrolled in the study. Patients who decide to participate will be entered into the study after obtaining their informed consent. They will receive the SIVA-MVP wearable and the associated accessories. They will be asked to rate their current cough severity on a visual analog scale (Cough Severity VAS) and fill in a Leicester Cough Questionnaire (LCQ) to assess the impact of cough on their quality of life. Participants will receive a second Cough Severity VAS and LCQ to fill at the end of the study and a return envelope. Participants will receive standard care and be asked to wear SIVA-MVP on their chest during the day and charge it on the bedside during sleep for 14 days. Every evening, they will be prompted by the SIVA-MVP smartphone application to indicate the timing of their main meals. On day 15, the study nurse will conduct a pre-scheduled phone interview with each participant. The phone interview will include instructing the patient to fill in the final Cough Severity VAS and LCQ, asking the questions of the Participant User Feedback Questionnaire, and instructing the patient to send the questionnaire forms and the SIVA-MVP wearable and the accessories back to the trial site using the return envelope. The Participant User Feedback Questionnaire will include ratings of wearing comfort, usability, and likeliness to wear for an extended period of time.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Informed Consent as documented by signature
- •Adult men and women at the date of signing the Informed Consent Form
- •Patients with a diagnosis or suspicion of refractory chronic cough or patients with a diagnosed asthma
- •Attending the treatment procedure as an outpatient
- •Comfortable with using a smartphone and willing to use an external iPhone daily for the duration of the study.
- •Adequate communication in US English (all study documentation and SIVA-MVP will be set to English language only).
Exclusion Criteria
- •Unable to make the decision to participate in a clinical study (e.g., seriously ill or unconscious subject, or subject with a mental or intellectual disability)
- •Inability to follow the procedures of the study, e.g., due to physical or intellectual impairment precluding informed consent or protocol adherence, psychological disorders (excluding depression) or dementia
- •Use of any other medical device equipment (e.g., portable oxygen concentrator, artificial cardiac pacemaker, implantable cardioverter-defibrillator)
- •Pregnancy: Female participants in child-bearing age without a negative pregnancy test (urine test). Female participants who are neither surgically sterilized / hysterectomized nor post-menopausal for longer than 2 years are considered to be of childbearing potential.
- •Known or suspected non-compliance, drug or alcohol abuse
- •Participation in another clinical study
Outcomes
Primary Outcomes
Performance of the SIVA-MVP cough detection device
Time Frame: First 24 hours
Validation of a SIVA-MVP performance of detecting individual cough events in a target population over a 24-hour validation phase (first 24 hours after baseline visit). Sensitivity, specificity, and positive and negative predictive values contribute to a description of cough monitor performance.
Secondary Outcomes
- Number of potential adverse events, serious adverse events, device deficiency and serious device deficiency(2 weeks)
- Comparison of objectively recorded (device) data and subjectively reported (patient) data measured with Leicester Cough Questionnaire and Cough Severity VAS(At Baseline and at the end of 2 weeks)
- Wearing time(2 weeks)
- Wearing comfort(2 weeks)
- Effective reply rate(2 weeks)
- Cough frequency patterns(2 weeks)